Literature DB >> 3956696

The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma.

V Bocci, M Muscettola, G Grasso, Z Magyar, A Naldini, G Szabo.   

Abstract

When human recombinant interferon-alpha 2 diluted in saline was injected s.c. into rabbits, the total amount recovered in thoracic lymph was less than 0.4%. Recoveries increased from 2- to 8-fold if interferon was injected in 4% albumin or with hyaluronidase, respectively. Albumin added to interferon acts as an interstitial fluid expander, thus favoring interferon absorption through lymphatics rather than blood capillaries. This strategy may increase the therapeutic index of interferon.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3956696     DOI: 10.1007/bf02118644

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  7 in total

1.  Pharmacokinetics of human leukocyte interferon.

Authors:  K Cantell; L Pyhälä
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

2.  Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice.

Authors:  A Billiau; H Heremans; D Ververken; J van Damme; H Carton; P de Somer
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

Review 3.  Evaluation of routes of administration of interferon in cancer: a review and a proposal.

Authors:  V Bocci
Journal:  Cancer Drug Deliv       Date:  1984

4.  The kidney is the main site of interferon catabolism.

Authors:  V Bocci; A Pacini; M Muscettola; G P Pessina; L Paulesu; L Bandinelli
Journal:  J Interferon Res       Date:  1982

5.  The physiological interferon response.

Authors:  V Bocci
Journal:  Immunol Today       Date:  1985-01

6.  Degradation of human 125I-interferon alpha by isolated perfused rabbit kidney and liver.

Authors:  V Bocci; K E Mogensen; M Muscettola; A Pacini; L Paulesu; G P Pessina; S Skiftas
Journal:  J Lab Clin Med       Date:  1983-06

7.  The role of liver in the catabolism of human alpha- and beta-interferon.

Authors:  V Bocci; A Pacini; L Bandinelli; G P Pessina; M Muscettola; L Paulesu
Journal:  J Gen Virol       Date:  1982-06       Impact factor: 3.891

  7 in total
  15 in total

Review 1.  Mechanistic determinants of biotherapeutics absorption following SC administration.

Authors:  Wolfgang F Richter; Suraj G Bhansali; Marilyn E Morris
Journal:  AAPS J       Date:  2012-05-23       Impact factor: 4.009

2.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

3.  Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats.

Authors:  Leonid Kagan; Michael R Turner; Sathy V Balu-Iyer; Donald E Mager
Journal:  Pharm Res       Date:  2011-09-02       Impact factor: 4.200

4.  Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies.

Authors:  Hao Lou; Michael J Hageman
Journal:  Pharm Res       Date:  2021-03-12       Impact factor: 4.200

Review 5.  Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.

Authors:  Yulia Vugmeyster; John Harrold; Xin Xu
Journal:  AAPS J       Date:  2012-07-14       Impact factor: 4.009

6.  Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application.

Authors:  A Supersaxo; W Hein; H Gallati; H Steffen
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

7.  Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration.

Authors:  Anas M Fathallah; Michael R Turner; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2014-12-20       Impact factor: 1.627

8.  Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics.

Authors:  Anas M Fathallah; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2014-11-19       Impact factor: 3.534

Review 9.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 10.  Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Michael R Turner; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2018-01-11       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.